Published in Am J Psychiatry on April 15, 2009
Relapse risk after discontinuation of risperidone in Alzheimer's disease. N Engl J Med (2012) 4.22
The long-term effects of conventional and atypical antipsychotics in patients with probable Alzheimer's disease. Am J Psychiatry (2013) 3.06
Undiagnosed illness and neuropsychiatric behaviors in community residing older adults with dementia. Alzheimer Dis Assoc Disord (2011) 0.98
Atypical antipsychotic use in patients with dementia: managing safety concerns. Am J Psychiatry (2012) 0.92
Second-generation antipsychotics in dementia: beyond safety concerns. A clinical, systematic review of efficacy data from randomised controlled trials. Psychopharmacology (Berl) (2010) 0.87
Antipsychotic-induced metabolic and cardiovascular side effects in schizophrenia: a novel mechanistic hypothesis. CNS Drugs (2013) 0.78
Nonsignificant weight gain with atypical antipsychotics in men with Alzheimer's Disease: an important result of the CATIE-Alzheimer's disease study. Am J Psychiatry (2009) 0.78
Alzheimer's disease: diagnosis and treatment across the spectrum of disease severity. Mt Sinai J Med (2011) 0.76
Effect of Psychotropic Drugs on Development of Diabetes Mellitus in Patients With Alzheimer's Disease. Medicine (Baltimore) (2015) 0.75
Management of Behavioral and Psychological Symptoms of Dementia. Noro Psikiyatr Ars (2014) 0.75
Atypical antipsychotics as add-on treatment in late-life depression. Clin Interv Aging (2016) 0.75
Psychosis. Continuum (Minneap Minn) (2015) 0.75
Effect of atypical antipsychotics on body weight in geriatric psychiatric inpatients. SAGE Open Med (2017) 0.75
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med (2005) 28.99
Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med (2006) 10.89
Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA (2005) 10.16
Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care (2004) 9.16
Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry (2006) 3.83
Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial. Am J Psychiatry (2008) 3.48
National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology. Am J Geriatr Psychiatry (2001) 2.74
A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology (1999) 2.51
A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry (2003) 2.50
The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. Cochrane Database Syst Rev (2006) 2.14
The Behavior Rating Scale for Dementia of the Consortium to Establish a Registry for Alzheimer's Disease. The Behavioral Pathology Committee of the Consortium to Establish a Registry for Alzheimer's Disease. Am J Psychiatry (1995) 2.11
Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry (2001) 2.06
Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophr Res (2008) 1.95
Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch Gen Psychiatry (2000) 1.93
Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. J Clin Psychiatry (1999) 1.86
Cardiovascular disease and Alzheimer's disease: common links. J Intern Med (2006) 1.74
Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia. Am J Geriatr Psychiatry (2005) 1.66
Using antipsychotic agents in older patients. J Clin Psychiatry (2004) 1.62
Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials. CMAJ (2004) 1.43
Diurnal variation in fasting plasma glucose: implications for diagnosis of diabetes in patients examined in the afternoon. JAMA (2000) 1.29
Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial. Am J Geriatr Psychiatry (2006) 1.12
Cardiovascular disease and risk of Alzheimer's disease. Neurol Res (2006) 1.04
Quetiapine to treat agitation in dementia: a randomized, double-blind, placebo-controlled study. Curr Alzheimer Res (2007) 1.03
Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease. Int J Geriatr Psychiatry (2004) 1.01
Olanzapine does not enhance cognition in non-agitated and non-psychotic patients with mild to moderate Alzheimer's dementia. Int J Geriatr Psychiatry (2005) 0.90
Risperidone in the treatment of psychosis of Alzheimer disease: results from a prospective clinical trial. Am J Geriatr Psychiatry (2006) 0.84
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med (2005) 28.99
Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry (2006) 12.41
Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med (2006) 10.89
A roadmap for the prevention of dementia II: Leon Thal Symposium 2008. Alzheimers Dement (2009) 10.21
Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA (2005) 10.16
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet (2013) 8.02
High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. JAMA (2008) 7.35
Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials (2004) 6.64
A roadmap for the prevention of dementia: the inaugural Leon Thal Symposium. Alzheimers Dement (2008) 6.39
Ambient air pollution and atherosclerosis in Los Angeles. Environ Health Perspect (2005) 6.19
Microduplications of 16p11.2 are associated with schizophrenia. Nat Genet (2009) 6.13
Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry (2007) 5.64
Medication augmentation after the failure of SSRIs for depression. N Engl J Med (2006) 5.16
Developing a national strategy to prevent dementia: Leon Thal Symposium 2009. Alzheimers Dement (2010) 4.85
Mood disorders in the medically ill: scientific review and recommendations. Biol Psychiatry (2005) 4.81
Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med (2011) 4.28
Relapse risk after discontinuation of risperidone in Alzheimer's disease. N Engl J Med (2012) 4.22
Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry (2006) 4.12
Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA (2009) 4.02
Is obesity associated with major depression? Results from the Third National Health and Nutrition Examination Survey. Am J Epidemiol (2003) 3.79
Atlas-based whole brain white matter analysis using large deformation diffeomorphic metric mapping: application to normal elderly and Alzheimer's disease participants. Neuroimage (2009) 3.74
Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry (2006) 3.72
Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. Am J Psychiatry (2013) 3.69
Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study. Lancet Neurol (2012) 3.48
Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial. Am J Psychiatry (2008) 3.48
Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia resulting from Alzheimer disease. Am J Geriatr Psychiatry (2006) 3.22
Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry (2006) 3.12
Physical activity, APOE genotype, and dementia risk: findings from the Cardiovascular Health Cognition Study. Am J Epidemiol (2005) 3.10
Impact of Angiotensin receptor blockers on Alzheimer disease neuropathology in a large brain autopsy series. Arch Neurol (2012) 3.07
Mania during treatment of chronic hepatitis C with pegylated interferon and ribavirin. Am J Psychiatry (2004) 2.82
Mobile interventions for severe mental illness: design and preliminary data from three approaches. J Nerv Ment Dis (2010) 2.80
Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. J Alzheimers Dis (2011) 2.78
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. Am J Psychiatry (2007) 2.75
Antihypertensive medication use and incident Alzheimer disease: the Cache County Study. Arch Neurol (2006) 2.71
Neuropathological basis of magnetic resonance images in aging and dementia. Ann Neurol (2008) 2.71
Depression and Bipolar Support Alliance consensus statement on the unmet needs in diagnosis and treatment of mood disorders in late life. Arch Gen Psychiatry (2003) 2.70
Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology (2006) 2.70
Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. Am J Psychiatry (2007) 2.68
Anti-aβ therapeutics in Alzheimer's disease: the need for a paradigm shift. Neuron (2011) 2.67
Florbetapir PET analysis of amyloid-β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study. Lancet Neurol (2012) 2.65
Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. N Engl J Med (2003) 2.63
Cognitive impact of subcortical vascular and Alzheimer's disease pathology. Ann Neurol (2006) 2.62
Systematic review of psychological approaches to the management of neuropsychiatric symptoms of dementia. Am J Psychiatry (2005) 2.61
Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res (2006) 2.60
Risk of mortality among individual antipsychotics in patients with dementia. Am J Psychiatry (2011) 2.59
What do people at risk for Alzheimer disease think about surrogate consent for research? Neurology (2005) 2.58
Ten-year predicted coronary heart disease risk in HIV-infected men and women. Clin Infect Dis (2007) 2.55
Ambient air pollution and the progression of atherosclerosis in adults. PLoS One (2010) 2.53
Effectiveness of switching from antipsychotic polypharmacy to monotherapy. Am J Psychiatry (2011) 2.52
Psychopathology in patients with degenerative cerebellar diseases: a comparison to Huntington's disease. Am J Psychiatry (2002) 2.52
Childhood air pollutant exposure and carotid artery intima-media thickness in young adults. Circulation (2012) 2.51
Barriers to employment for people with schizophrenia. Am J Psychiatry (2006) 2.42
Effectiveness of switching antipsychotic medications. Am J Psychiatry (2006) 2.38
Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study. Int J Geriatr Psychiatry (2008) 2.32
Perspectives on depression, mild cognitive impairment, and cognitive decline. Arch Gen Psychiatry (2006) 2.29
The schizophrenia drug-treatment paradox: pharmacological treatment based on best possible evidence may be hardest to practise in high-income countries. Br J Psychiatry (2006) 2.24
Postmenopausal hormone therapy in clinical perspective. Menopause (2007) 2.23
A national study of violent behavior in persons with schizophrenia. Arch Gen Psychiatry (2006) 2.23
Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study. Clin Ther (2010) 2.19
Meta-analysis of six-month memantine trials in Alzheimer's disease. Alzheimers Dement (2007) 2.18
Alzheimer's prevention initiative: a proposal to evaluate presymptomatic treatments as quickly as possible. Biomark Med (2010) 2.17
Mild behavioral impairment and risk of dementia: a prospective cohort study of 358 patients. J Clin Psychiatry (2009) 2.16
Progesterone receptors: form and function in brain. Front Neuroendocrinol (2008) 2.15
Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD. Am J Psychiatry (2011) 2.15
The timing hypothesis and hormone replacement therapy: a paradigm shift in the primary prevention of coronary heart disease in women. Part 1: comparison of therapeutic efficacy. J Am Geriatr Soc (2013) 2.11
Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia. Br J Psychiatry (2008) 2.10
Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology (2012) 2.08
The Maryland Assisted Living Study: prevalence, recognition, and treatment of dementia and other psychiatric disorders in the assisted living population of central Maryland. J Am Geriatr Soc (2004) 2.01
Alpha-tocopherol supplementation in healthy individuals reduces low-density lipoprotein oxidation but not atherosclerosis: the Vitamin E Atherosclerosis Prevention Study (VEAPS). Circulation (2002) 1.99
Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force. Alzheimers Dement (2013) 1.98
Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Lancet Neurol (2007) 1.97